← All Bristol Myers Squibb CO filings

Bristol Myers Squibb CO Form 4 insider transactions

NYSE
BMY
Bristol Myers Squibb CO
Form 4: Bristol-Myers Squibb CEO Christopher Boerner Reports Changes in Beneficial Ownership
CEO Christopher Boerner reports transactions involving Bristol-Myers Squibb common stock and market share/performance units, including vesting, adjustments, and tax withholdings.
NYSE
BMY
Bristol Myers Squibb CO
Form 4: Bristol-Myers Squibb Executive Karin Shanahan Reports Changes in Beneficial Ownership
EVP Karin Shanahan reports transactions involving Bristol-Myers Squibb stock and derivative securities, including the cancellation and acquisition of market share units and performance shares.
NYSE
BMY
Bristol Myers Squibb CO
Form 4: Bristol-Myers Squibb Executive Gregory Scott Meyers Reports Changes in Beneficial Ownership
EVP, Chief Digital & Tech Officer of Bristol-Myers Squibb, Gregory Scott Meyers, reports acquisition and disposal of market share units and performance shares.
NYSE
BMY
Bristol Myers Squibb CO
Form 4: Bristol-Myers Squibb Executive Acquires Market Share and Performance Share Units
Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reports acquisition of market share units and performance shares.
NYSE
BMY
Bristol Myers Squibb CO
Form 4: Bristol-Myers Squibb CFO David Elkins Reports Changes in Beneficial Ownership
David Elkins, EVP and CFO of Bristol-Myers Squibb, reports transactions involving common stock and derivative securities, including vesting of market share units and performance shares.
NYSE
BMY
Bristol Myers Squibb CO
Form 4: Bristol-Myers Squibb Executive Chair Giovanni Caforio Reports Stock Transactions
Giovanni Caforio, Executive Chair of Bristol-Myers Squibb, reports transactions involving common stock and market share units, including vesting, adjustments, and shares withheld for taxes.
NYSE
BMY
Bristol Myers Squibb CO
Form 4: Bristol-Myers Squibb Executive Acquires Restricted Stock Units
Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reports the acquisition of 9,858 restricted stock units (RSUs) that will vest over three years.